RESEARCH USE ONLY. UK DISPATCH. ≥98% PURITY. SAME DAY DISPATCH BEFORE 2 PM MON–FRI. NOT FOR HUMAN CONSUMPTION
Lynx Peptides
Basket 0

Human clinical evidence

PT-141 research overview

Review the published research context, areas studied and evidence limitations associated with this catalogue material.

Evidence context statedSources linkedLast reviewed

Research context

PT-141 is identified in published literature as bremelanotide, a melanocortin receptor agonist investigated in controlled human pharmacology and phase 3 trials.

Areas studied

  • Melanocortin receptor agonism
  • Human pharmacology
  • Controlled clinical endpoints
  • Safety and tolerability

Limitations and investigational status

The cited studies concern defined clinical formulations and selected adult populations. They do not establish equivalence to catalogue research material or support unsupervised human use.

References

  1. 1Diamond et al. - Journal of Clinical Pharmacology, 2004
  2. 2Kingsberg et al. - Obstetrics and Gynecology, 2019

For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.